feed,title,long_url,short_url
Benzinga,Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment,https://benzinga.com/analyst-ratings/analyst-color/23/05/32515452/unlocking-a-750-million-opportunity-krystal-biotechs-vyjuvek-and-its-potent-impact-,https://da.gd/yZX5Mm
